Certara’s Q2 2026 earnings reveal a mixed but promising picture: software revenue surged 4% (now 53% of total revenue), while services dipped 3%, signaling a strategic pivot toward digital tools. The company trimmed costs, cut 5% of global staff, and sold off non-core assets to sharpen focus — all aimed at boosting margins and predictability. AI is now central to their engine, powering 85% of new code and driving productivity gains across products like CoAuthor’s 600+ AI agents. With 2,600 clients and regulatory wins — including every FDA-approved novel therapy this quarter — Certara is positioning itself as the AI-driven leader in model-informed drug development, poised to accelerate patient impact.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
